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Introduction {#sec005}
============

Breast cancer remains to be the major cancer diagnosis in women. Approximately 65% of the invasive breast cancer patients are aged 40--70 years at initial diagnosis and about 30% of the breast cancer patients are 70 years or older \[[@pone.0229518.ref001]\]. Survival rates have not improved in elderly patients throughout the years while mortality rates in younger patients have significantly decreased during the last 20 years \[[@pone.0229518.ref002]\]. The treatment of elderly breast cancer patients differs from the therapeutic approach in younger ones, as elderly patients are prone to geriatric frailty and comorbidities, such as renal failure, liver disease, and/or cerebrovascular disease \[[@pone.0229518.ref003]--[@pone.0229518.ref005]\]. Moreover, those tumors in elderly patients are often of less aggressive tumor biology.

Postoperative radiotherapy (RT) is the most effective intervention to prevent local relapse after breast conserving surgery (BCS) \[[@pone.0229518.ref006]\]. In different meta analyses, hazard ratios of 0.2--0.35 have been described meaning that up to eight of ten relapses can be avoided by RT \[[@pone.0229518.ref006]--[@pone.0229518.ref008]\]. As a result of the improved local tumor control, it has been previously stated that breast cancer related mortality has been significantly decreased during the last decades \[[@pone.0229518.ref006]\]. Therefore, it has been a general recommendation to perform BCS only in combination with postoperative radiotherapy \[[@pone.0229518.ref009]\]. If patients cannot or will not accept postoperative RT, mastectomy is the alternative surgical treatment \[[@pone.0229518.ref010]\]. However, subgroups have been defined that are associated with a low risk for locoregional recurrence (pT1, pN0, R0, HER2-) \[[@pone.0229518.ref011], [@pone.0229518.ref012]\]. In those cases, radiotherapy still adds benefits but can most likely be dispensed even after BCS.

Accelerated partial breast irradiation (APBI) providing radiation therapy to the tumor bed at a higher dose per fraction based on the radiobiologic equivalence is an advisable postoperative approach in properly selected elderly patients, combining advantages of a radical approach that minimizes the risk of undertreatment with efficient reduction of redundant irradiated volume \[[@pone.0229518.ref013], [@pone.0229518.ref014]\]. Similarly, shortened (hypofractionated) dose fraction schedules may be more convenient for older patients \[[@pone.0229518.ref015]\].

Methods {#sec006}
=======

Patients {#sec007}
--------

The BRENDA (breast cancer care under evidence-based guidelines) collective included patients with breast cancer from the Department of Gynecology and Obstetrics at the University of Ulm and from 16 partner clinics in Germany for the period 2001--2009. The exact conditions and inclusion criteria of BRENDA have been described previously \[[@pone.0229518.ref016]\]. For this retrospective study, we extracted data of 2384 patients aged 70 years and older with primary M0 breast cancer. All patients participated after written and informed consent. If any information in the database was missing or conflicting, a verification using the original patient file was done. Initial tumor staging and annual follow-up were carried out according to usual recommendations. If the patient was lost to follow-up, data were censored at the date of the last known contact. Adjuvant treatments were checked for guideline adherence. Guideline adherence was defined based on a systematic analysis of the guideline recommendations and statements of the interdisciplinary consensus S3 guideline issued by the German Cancer Society in 2008. A comparison of the treatment recommendations of the S3-guideline and other national breast cancer guidelines from the USA (NCCN, ASCO), Canada (CCO), Australia (NBOCC) and the UK (NICE, SIGN) showed that these guidelines differ only marginally \[[@pone.0229518.ref017]\]. Recurrence-free survival (RFS) is a composite end point including the following events: Invasive recurrence in the ipsilateral breast or locoregionally, at a distant site, or death from breast cancer.

Surrogate definition of intrinsic subtypes {#sec008}
------------------------------------------

To define the intrinsic breast cancer subtypes hormone receptor expression (HR), HER2 expression and cell proliferation marker Ki67 are generally used \[[@pone.0229518.ref018], [@pone.0229518.ref019]\]. As Ki67 was not available in the BRENDA database, we used grading as a surrogate parameter to include the cell proliferation, as described before e.g. by Parise et al. \[[@pone.0229518.ref020]\], von Minckwitz et al. \[[@pone.0229518.ref021]\] and Lips et al. \[[@pone.0229518.ref022]\]. The 5 intrinsic subtypes are defined as follows: Luminal A (HR+/HER2−/grade1 or 2), luminal B-HER2-negative like (HR+/HER2−/ grade 3), luminal B-HER2-positive like (HR+/HER2+, all grades); HER2-overexpressing (non-luminal, HR−/HER2+) and triple-negative (basal-like, HR−/ HER2−).

Statistical analysis {#sec009}
--------------------

Patient characteristics were described with percentages, mean values and standard deviations (SD). When no information was available, the status was coded as missing data. Statistical comparisons for categorical data are carried out using the χ2 test. The distribution of a continuous parameter across a binary variable was tested using the independent-samples Mann-Whitney U test. Survival distributions and median survival times are estimated using the Kaplan--Meier product-limit method. The log-rank test was used to compare survival rates. The Cox proportional hazards model was used to estimate the hazard ratio and confidence intervals. Proportional hazards were tested for all entered variables using statistical and graphical methods (Schoenfeld residuals and log--log plot of cumulative hazard). Confidence intervals for the regression coefficients are based on the Wald statistics. We used hierarchical models to check whether interactions of multivariate significant variables could improve the model.

Furthermore, we additionally tested if there is a difference between two or more survival curves using the G^p^ family of tests of Harrington and Fleming \[[@pone.0229518.ref023]\], with weights on each death of S(t)^p^, where S(t) is the Kaplan-Meier estimate of survival. With rho = 0 this is the log-rank or Mantel-Haenszel test, and with rho = 1 it is equivalent to the Peto & Peto modification of the Gehan-Wilcoxon test.

A non-inferiority log rank test with an overall sample size of 599 low risk patients with GA-BCS (542 in the group with GA-RT and 57 in the group without GA-RT) achieves 80.0% power at a 0.05 significance level to detect an equivalence hazard ratio of 1.40 when the actual hazard ratio is an equivalence hazard ratio of 1.00 and the reference group hazard rate is 0.97. Taking 1.30 instead of 1.40 we need in the low risk group with GA-BCS 911 patients with GA-RT and 96 patients without GA-RT. P-values less than 0.05 were considered statistically significant. Statistical analyses were two sided and carried out using R 3.5, SPSS 26 (IBM) and NCSS 10 for Windows.

Results {#sec010}
=======

Basic characteristics {#sec011}
---------------------

Basic patient characteristics are listed in [Table 1](#pone.0229518.t001){ref-type="table"}. The median observation time was 46 months (mean 48.9±24.8 months). 39,8% (n = 950) were low-risk and 60,2% (n = 1434) were higher-risk. 54,4% patients received GA-BCS of which 85% (n = 1103) received GA-RT and 15% did not obtain GA-RT. 14.6% (n = 349) obtained GA-mastectomy. There was a relatively large number of patients who obtained mastectomy (n = 652; 27.3%), although it was not indicated by the S3-guideline. In the low risk group 29% (n = 276) obtained mastectomy out of which 78% (n = 214) were not GA. Altogether 66% (n = 1583) of the elderly patients were not treated 100% GA (low risk: 50% GA; higher-risk: 77% GA). Low risk patients with GA-BCS but without GA-RT were significantly (p\<0.001) older than corresponding patients with GA-RT (median age: 75y vs. 80y). 89.3% of the low-risk patients with GA-BCS were treated with hormonal therapy.

10.1371/journal.pone.0229518.t001

###### Basic characteristics of all elderly patients ≥ 70 years included in this analysis.

![](pone.0229518.t001){#pone.0229518.t001g}

                                                          Total                               low risk                          higher risk                        asymptotic and exact significance[\*](#t001fn001){ref-type="table-fn"}   
  ------------------------------------------------------- ----------------------------------- --------------------------------- ---------------------------------- ------------------------------------------------------------------------ ----------
  age at diagnosis                                        mean: 77.6 (SD 5.6) (median:77.0)   mean: 76.9 (SD 5.1) (median:76)   mean: 78.0 (SD 5.9) (median: 77)   \<0.001                                                                  
  Range: 70--100                                          Range: 70--97                       Range:70--100                                                                                                                                 
  age groups                                              70-74y                              847(35.5)                         365(38.4)                          482(33.6)                                                                0.002
  75-79y                                                  717(30.1)                           298(31.4)                         419(29.2)                                                                                                   
  ≥ 80y                                                   820(34.4)                           287(30.2)                         533(37.2)                                                                                                   
  T-categories                                            T1 or T2                            2209(92.7)                        950(100)                           1259(87.8)                                                               \< 0.001
  T3 or T4                                                175(7.3)                            0(0.0)                            175(12.2)                                                                                                   
  grading                                                 G1                                  207(8.7)                          141(14.8)                          66(4.6)                                                                  \<0.001
  G2                                                      1571(66.0)                          809(85.2)                         766(53.4)                                                                                                   
  G3                                                      602(25.3)                           0(0.0)                            602(42.0)                                                                                                   
  nodal status                                            nodal negative                      1367(59.9)                        950(100.0)                         417(31.3)                                                                \< 0.001
  1--3 affected lymph nodes                               512(22.4)                           0(0.0)                            512(38.5)                                                                                                   
  \>3 affected lymph nodes                                402(17.6)                           0(0.0)                            402(30.2)                                                                                                   
  intrinsic subtypes                                      Luminal A                           1561(65.5)                        950(100)                           611(42.6)                                                                \< 0.001
  Luminal B/HER2-                                         341(14.3)                           0(0.0)                            341(23.8)                                                                                                   
  Luminal B/HER2+                                         225(9.4)                            0(0.0)                            225(15.7)                                                                                                   
  TNT                                                     174(7.3)                            0(0.0)                            174(12.1)                                                                                                   
  HER2 overexpressing                                     83(3.5)                             0(0.0)                            83(5.8)                                                                                                     
  100% guideline adherence                                non-adherent                        1583(66.4)                        477(50.2)                          1106(77.1)                                                               \< 0.001
  adherent                                                801(33.6)                           473(49.8)                         328(22.9)                                                                                                   
  guideline adherent breast conserving therapy (GA-BCS)   carried out---guideline adherent    1298(54.4)                        654(68.8)                          644(44.9)                                                                \< 0.001
  carried out---guideline non-adherent                    85(3.6)                             20(2.1)                           65(4.5)                                                                                                     
  not carried out---guideline adherent                    349(14.6)                           62(6.5)                           287(20.0)                                                                                                   
  not carried out---guideline non adherent                652(27.3)                           214(22.5)                         438(30.5)                                                                                                   
  guideline adherent radiotherapy (GA-RT)                 carried out---guideline adherent    1362(57.1)                        611(64.3)                          751(52.4)                                                                \< 0.001
  carried out---guideline non-adherent                    88(3.7)                             21(2.2)                           67(4.7)                                                                                                     
  not carried out---guideline adherent                    553(23.2)                           251(26.4)                         302(21.1)                                                                                                   
  not carried out---guideline non adherent                381(16.0)                           67(7.1)                           314(21.9)                                                                                                   
  adjuvant systemic therapy (AST)                         no AST                              440(18.5)                         113(11.9)                          327(22.8)                                                                \< 0.001
  hormonal therapy                                        1566(65.7)                          818(86.1)                         748(52.2)                                                                                                   
  chemotherapy                                            141(5.9)                            6(0.6)                            135(9.4)                                                                                                    
  hormonal+chemotherapy                                   237(9.9)                            13(1.4)                           224(15.6)                                                                                                   

\*The asymptotic significance of the chi-square test and the significance of Fisher's exact test are in our case identical at least to 3 decimal places.

Recurrence free survival (RFS) and breast cancer-specific survival (BCSS) {#sec012}
-------------------------------------------------------------------------

There was no significant (log rank p = 0.470) difference in RFS stratified by the 3 age groups ([Fig 1](#pone.0229518.g001){ref-type="fig"}). Differences in RFS were significantly different (log rank p\<0.001) when stratified by GA-RT in the whole collective of early breast cancer patients ≥ 70 years old ([Fig 2](#pone.0229518.g002){ref-type="fig"}). There was a significant difference (log rank p\<0.001) in RFS stratified by risk ([Fig 3](#pone.0229518.g003){ref-type="fig"}). No significant differences were found when analyzing RFS for low-risk early breast cancer patients stratified by BCS versus mastectomy ([Fig 4](#pone.0229518.g004){ref-type="fig"}).

![Recurrence free survival for early breast cancer patients aged ≥ 70 years.\
Kaplan-Meier curves of recurrence free survival for early breast cancer patients aged 70 years and older, stratified by age.](pone.0229518.g001){#pone.0229518.g001}

![Recurrence free survival for early breast cancer patients aged ≥ 70 years.\
Kaplan-Meier curves of recurrence free survival for early breast cancer patients aged 70 years and older, stratified by guideline-adherent radiotherapy.](pone.0229518.g002){#pone.0229518.g002}

![Recurrence free survival for early breast cancer patients aged ≥ 70 years.\
Kaplan-Meier curves of recurrence free survival for early breast cancer patients aged 70 years and older, stratified by risk. Low risk: luminal A and T1/T2 and node-negative. Higher-risk: other than luminal A or G3 or T3/T4 or node-positive.](pone.0229518.g003){#pone.0229518.g003}

![Recurrence free survival for early breast cancer patients aged ≥ 70 years.\
Kaplan-Meier curves of recurrence free survival for low risk early breast cancer patients aged 70 years and older stratified by BCS vs. mastectomy. Low risk: luminal A and T1/T2 and node-negative.](pone.0229518.g004){#pone.0229518.g004}

For low risk patients with GA-BCS there was no significant difference in RFS (log rank p = 0.651; [Fig 5a](#pone.0229518.g005){ref-type="fig"}) and tumor-associated overall survival (OS) (log rank p = 0.573; [Fig 5b](#pone.0229518.g005){ref-type="fig"}) stratified by RT. 5 years RFS for low risk patients with GA-RT as well as for low risk patients without GA-RT were \> 97%. In contrast, for higher-risk patients with GA-BCS there were significant differences in RFS (log rank p\<0.001; [Fig 6a](#pone.0229518.g006){ref-type="fig"}) and in BCSS (log rank p = 0.026; [Fig 6b](#pone.0229518.g006){ref-type="fig"}) stratified by GA-RT.

![Recurrence free and tumor-associated overall survival for early breast cancer patients aged ≥ 70 years stratified by guideline adherent radiotherapy.\
(A) Kaplan-Meier curves of recurrence free survival for low risk early breast cancer patients aged 70 years and older with guideline adherent BCS stratified by guideline adherent RT. Low risk: luminal A and T1/T2 and node-negative. (B): Kaplan-Meier curves of tumor-associated overall survival for low-risk early breast cancer patients aged 70 years and older with guideline adherent BCS stratified by guideline adherent RT.](pone.0229518.g005){#pone.0229518.g005}

![Recurrence free and tumor-associated overall survival for early breast cancer patients aged ≥ 70 years stratified by guideline adherent radiotherapy.\
(A) Kaplan-Meier curves of recurrence free survival for higher-risk early breast cancer patients aged 70 years or older with guideline adherent BCS stratified by guideline adherent RT. Higher-risk: other than luminal A or G3 or T3/T4 or node-positive. (B) Kaplan-Meier curves of tumor-associated overall survival for higher-risk early breast cancer patients aged 70 years or older with guideline adherent BCS stratified by guideline adherent RT. Higher-risk: other than luminal A or G3 or T3/T4 or node-positive.](pone.0229518.g006){#pone.0229518.g006}

The results do not change with regard to RFS after adjusting by adjuvant systemic therapy (AST) (RFS: low risk p = 0.651; HR = 1.44; 95% CI. (0.33--6.37); higher-risk p = 0.001; HR = 2.86; 95% CI. (1.54--5.31); [Fig 7a and 7b](#pone.0229518.g007){ref-type="fig"}).

![Cox regression of recurrence free survival for early breast cancer patients aged ≥ 70 years adjusted by adjuvant systemic therapy (AST) and physical status.\
(A) Cox regression of recurrence free survival for low risk early breast cancer patients aged 70 years or older with guideline adherent BCS stratified by guideline adherent RT and adjusted by adjuvant systemic therapy (AST), ASA physical status classification system and the New York Heart Association (NYHA) functional classification. Low risk: luminal A and T1/T2 and node-negative. (B) Cox regression of recurrence free survival for higher-risk early breast cancer patients aged 70 years or older with guideline adherent BCS stratified by guideline adherent RT and adjusted by adjuvant systemic therapy (AST), ASA physical status classification system and the New York Heart Association (NYHA) functional classification. Higher-risk: other than luminal A or G3 or T3/T4 or node-positive.](pone.0229518.g007){#pone.0229518.g007}

Additional testing if there is a difference between two or more survival curves using the G^p^ family of tests of Harrington and Fleming, we also found no significant difference in RFS and in BCSS for low-risk patients with GA-BCS stratified by RT (p = 0.7 and p = 0.6).

Altogether we found, that low risk early breast cancer patients aged 70 and older with GA-BCS without breast irradiation had a chance of relapse of \< 3% in 5 years, whereas for elderly higher-risk patients the risk of relapse is up to 9% higher without GA-RT. As a side effect of these results, removing the entire breast of elderly low risk patients seems to have no significant impact on the RFS.

If we restrict our analysis to a similar subgroup of patients as in the CALGB 9343 \[[@pone.0229518.ref008]\] (age \> 70 years with clinical stage I, ER-positive breast cancer treated with lumpectomy followed by hormonal therapy) irradiation adds no significant benefit in terms of recurrence free survival (log rank p = 0.653) and of BCSS (log rank p = 0.662). The CALGB 9343 trial, as well as this study define two types of low risk patients, which both don´t need RT. Therefore, we can combine these two subsets to a new subset of low risk patients defined by (age \> 70 years, luminal A and T1/T2 and node-negative treated with BCS) or (age \> 70 years with clinical stage I, ER-positive breast cancer, treated with BCS followed by hormonal therapy). For this combined subgroup we have no significant difference in RFS (log rank p = 0.958) and BCSS (log rank p = 0.506).

Discussion {#sec013}
==========

Our study was based on comprehensive analyses of outcomes of elderly patients with primary breast cancer who did or did not receive breast irradiation following breast-conserving surgery using the multi-center BRENDA Registry. The major goal of the study was to classify those elderly patients who may have no profit of breast irradiation following GA-BCS. The most important findings of the present study were the following: Low-risk early breast cancer patients aged 70 years and older who receive GA-BCS are a subgroup in which breast irradiation seems to add no significant benefit in terms of recurrence free and tumor-associated survival. The chance of relapse within 5 years is \<3%.For elderly higher-risk patients, breast irradiation should be used routinely following GA-BCS.Removing the entire breast of elderly low-risk patients to spare them from breast irradiation seems not to be necessary. These patients can obtain BCS without breast irradiation.

In order to reduce morbidity and to increase efficacy of breast cancer treatments, individual tailoring of treatment strategies is needed. Since elderly patients are often presented with several co-morbidities and a wish for de-escalation of therapy, adjuvant therapy components should be reconsidered regarding the expected benefit on the outcome.

In this work, elderly patients received BCS in 58%, while 42% had mastectomy. Interestingly, 652 (27,3%) patients obtained mastectomy even if the guidelines would have recommended to perform BCS while only 85 (3,6%) had BCS instead of mastectomy. This effect has been previously described, showing that elderly patients receive mastectomy more often when compared to younger patients, even if guidelines indicated the contrary \[[@pone.0229518.ref024], [@pone.0229518.ref025]\]. Reasons for substandard performance of mastectomies might be the patients wish for final surgical treatment without relevant risk for follow-up resections or local recurrence or physicians\`attempt to avoid further adjuvant treatment such as RT. Regardless, mastectomy comes along with relevant morbidity since it has been previously shown that wound infection rates including deep infection and dehiscence occur significantly more often than in patients receiving BCS \[[@pone.0229518.ref026]\].

Regarding the survival, we showed that 10-years RFS among elderly patients is in general high and there is no significant difference between patients aged 70--74 years and those older than 80 years. In comparison to older publications survival rates are comparable. Large prospective trials described 10-years RFS rates of around 90% in women diagnosed with early breast cancer between 1994 and 1999 that received endocrine therapy only, while those receiving RT and endocrine therapy showed 98% RFS \[[@pone.0229518.ref008]\]. Especially, among patients older than 70 years and low-risk early breast cancer, 10-years RFS is excellent, regardless of the different surgical treatments.

For several decades, scientific approaches have been made to analyze if patients could be identified in whom RT might be omitted. All the studies differed conceptually including not only elderly patients but also different tumor sizes or systemic therapies. In summary, no significant differences have been shown regarding OS but some decreases in in-breast recurrences after RT \[[@pone.0229518.ref027]--[@pone.0229518.ref029]\] as recent meta-analyses confirmed \[[@pone.0229518.ref030], [@pone.0229518.ref031]\]. Interestingly, there is also some evidence that effects of RT also depend on histopathologic subtypes since RT did not improve OS in patients with invasive lobular or uncommon invasive breast cancer types \[[@pone.0229518.ref032]\].

In our study, we evaluated that in 85% BCS and adjuvant RT were carried out guideline-adherently. The remaining 15% did not receive RT. To evaluate the effect of radiotherapy in the current, prevalent collective of elderly patients we aimed to analyze the different subtypes according to tumor biology. We found that the significantly beneficial effect of RT on RFS was limited to elderly patients with higher-risk early breast cancer. Elderly patients with low-risk early breast cancer instead, showed anyhow excellent RFS and did not significantly profit from adjuvant RT. Also Kunkler et al. stated, that the 5-year ipsilateral breast tumor recurrence rate is probably low enough for women older than 65 years to forgo radiotherapy after BCS \[[@pone.0229518.ref007]\]. De Boer et al. recently showed that recurrence risk in elderly patients aged ≥ 75 years with T1-2N0 breast cancer was low, even without radiotherapy \[[@pone.0229518.ref033]\].

The results of the long-term follow-up of CALGB 9343 \[[@pone.0229518.ref008]\] confirm that in the subgroup of women aged \> 70 years with clinical stage I, ER-positive breast cancer treated with lumpectomy followed by tamoxifen, irradiation adds no significant benefit in terms of survival, time to distant metastasis, or ultimate breast preservation. In addition to CALGB 9343, we showed the direct difference of effects in a high number of elderly women between higher-risk and low-risk situation. Especially, these results did not change when we stratified by RT and in addition adjusted by adjuvant systemic therapy and comorbidity (ASA and NYHA).

National Comprehensive Cancer Network (NCCN) Guidelines for older women have already recommended omission of RT in elderly patients earlier after the publication of the CALGB 9343 study. Examination of factors associated with a change in RT use in elderly patients with breast cancer showed that age, comorbidity and small tumors were significantly associated with an omission of RT. But the authors also concluded that the use of RT in elderly women was also associated with the treating institution. In this case, the implementation of change in the clinical guidelines showed a wide variety \[[@pone.0229518.ref034]\]. Moreover, Chu et al. analyzed that RT usage decreased from 71.6% to 67.5% after the publication of CALGB study showing a minimal impact on clinical daily routine concerning RT in older breast cancer patients \[[@pone.0229518.ref035]\]. In order to improve the implementation of guidelines in these elderly patients protocols including life expectancy estimate and geriatric assessment have been described \[[@pone.0229518.ref036]\].

Limitations {#sec014}
-----------

Some limitations need to be considered. First, this study has the limitations inherent to a retrospective study. Second, the number of low risk patients with BCS and without RT is small (n = 62). Third, low risk patients with BCS and without RT were significantly older than low risk patients with BCS and RT.

Conclusions {#sec015}
===========

We conclude that elderly patients could be counselled about indications of limited benefit of adjuvant radiotherapy on the outcome in case of low-risk early breast cancer diagnosis. Elderly patients with higher-risk breast cancer should instead be informed about the beneficial effect of adjuvant RT.

This fact will remain one of several others in order to achieve an individualized treatment strategy for our patients.

We gratefully thank the whole BRENDA study team for their contributions.

10.1371/journal.pone.0229518.r001
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: You state" The treatment of elderly breast cancer patients differs from the therapeutic approach in younger ones, as elderly patients are prone to geriatric frailty and comorbidities, such as renal failure, 94 liver disease, and/or cerebrovascular disease (3-5)."

Please add that the treatment also changes because the cancers are less aggressive (Even within ER +, elderly seem more responsive to endocrine therapy as the percent ER positivity is higher.)

You over state the benefits of RT:

"After evaluation of different subtypes of breast cancer, it is obvious that even those with less aggressive molecular types profit from radiotherapy. In different meta analyses, hazard ratios of 0.2-0.35 have been described meaning that up to eight of ten relapses can be avoided by RT (6-8). As a result of the improved local tumor control, it has been previously stated that breast cancer related mortality has been significantly decreased during the last decades (6). Therefore, it has been a general recommendation to perform BCT only in combination with postoperative radiotherapy (9). If patients cannot or will not accept postoperative RT, mastectomy is the alternative surgical treatment (10). However, subgroups have been defined that are associated with a low risk for recurrence (pT1, pN0, R0, HER2-) (11, 12). In those cases, radiotherapy still adds benefits but can most likely be dispensed even after BCT."

No randomized trial has shown a survival benefit to RT in early breast cancer.

Always state "locoregional" recurrence, as RT has no impact on distant recurrence in randomized trials.

You never defined intermediate vs high risk or separated out those groups. These need to be defined.

You combine intermediate and high risk into a single group without showing that they act similarly. You need to describe why you made this combination.

In some places you state high risk benefits and in others that intermediate or high risk benefits, but I do not see these differentiated in your data

Your intermediate group likely contains patients that fit the randomized trials that showed RT has not beneficial. (Such as a 1 cm Grade 3 cancer.). If you are using retrospective data to invalidate the conclusions of a randomized trial, please state why you think this is defensible.

When you state that limiting your analysis to 9343 criteria, are you including intermediate and high risk patients who meet that criteria? If so, does that negate your statement that intermediate and high risk need RT?

Reviewer \#2: The manuscript here is technically sound and adds additional important information to the literature using a relatively large database of elderly women with breast cancer. The manuscript could be simpler and clearer and my suggestions are below:

1\. The use of the terms BCT with and without RT is confusing. If I'm not mistaken breast conserving therapy without radiotherapy should be referred to as BCS (breast conserving surgery). BCT implies the use of radiotherapy.

2\. I generally disagree with intro lines 102-104. There has been enough data on low risk patients with small tumors having low recurrence rates without radiotherapy that these statements do not apply in 2019.

3\. I'm not sure why the authors separated the groups out by low and intermediate/high. They define the patients that they place in this intermediate/high group but never define the difference between intermediate and high. This should be defined at some point.

4\. There are a great deal of words in the paragraph called "basic characteristics" and it is a difficult read. It is essentially explaining Table 1. The paragraph could be started by simply stating that "Basic patient characteristics are listed in Table 1" and then just point out a couple of important distinctions. I do not feel this large paragraph is necessary.

5\. I find the terms throughout the manuscript of guideline adherent and guideline non-adherent confusing. One could simply state that guidelines state that radiotherapy is indicated and compare the difference between those having it and those not having it. It also makes the Figures showing relapse free and overall survival confusing.

6\. Discussion could be much simpler. Prime 2 and CALGB trials are referenced early on and then a paragraph is allotted to each one later in the discussion. I would just acknowledge each randomized control trial once and shorten discussion.

7\. Overall useful information particularly regarding the higher risk group but could be more simply and clearly presented.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

12 Jan 2020

Additional Editor comments:

Major points:

-The intrinsic types of breast cancer are not defined according to prior studies (PMID: 29132568).

Thank you for this comment. As we mentioned in the section "Surrogate Definition of intrinsic subtypes" expression of hormone receptors, HER2 and analysis of Ki67 is generally used to define the intrinsic subtypes in breast cancer. Unfortunately, Ki67 was not available in our database. Therefore, the distinction between Luminal A and B was a challenge. Based on the publications of Minckwitz et al., Parise et al. and Lips et al. we used grading as a surrogate parameter for Ki67 as we did in all our previous BRENDA publications.

Anyway, the analysis and interpretation of the marker Ki67 is complex as some studies have used 10%, 14% or 20% as cut-off value. This problem is also discussed in PMID: 29132568 you mentioned.

-Fisher exact test should be used in some subgroups\' analyses, instead of Chi-square test.

As we all know, the usual rule of thumb for deciding whether the chi-squared approximation is good enough is that the chi-squared test is not suitable when the expected values in any of the cells of a contingency table are below 5, or below 10 when there is only one degree of freedom. In our case we have no cells with an expected frequency of less than 5. Therefore, the chi-square test is good enough.

Nevertheless, we additionally calculated Fisher's exact test beside of two other tests (likelihood ratio and linear by linear association).

The asymptotic significance of the chi-square test and the exact significance of Fisher's exact test are in our case identical at least to 3 decimal places. Therefore, we renamed "significance" in table 1 "basic characteristics" to "asymptotic and exact significance".

Here are the results

Age groups

T categories

Grading

Nodal status

Intrinsic subtypes

100% guideline adherence

Guideline adherent breast conserving therapy (BCT)

Guideline adherent radiotherapy

Adjuvant systemic therapy (AST)

-Please compare the characteristics of the subgroups that were generated by PSM-IPW grouping. I.e. to test whether PSM-IPW worked.

Thank you for this very interesting comment. We compared the characteristics of the subgroups that were generated by PSM-IPW grouping and indeed, in our case PSM-IPW increases the imbalance between the groups. This is just what Gary King and Richard Nielsen (2018) stated in their publication "Why Propensity Scores Should Not Be Used for Matching" (although propensity score matching is an enormously popular method of preprocessing data for causal inference) \[27\]. They showed that "PSM often accomplishes the opposite of its intended goal --- thus increasing imbalance, inefficiency, model dependence, and bias. The weakness of PSM comes from its attempts to approximate a completely randomized experiment, rather than, as with other matching methods, a more efficient fully blocked randomized experiment. PSM is thus uniquely blind to the often large portion of imbalance that can be eliminated by approximating full blocking with other matching methods."

Therefore, we no longer use PSM-IPW. We test now if there is a difference between two or more survival curves using the Gp family of tests of Harrington and Fleming (1982), with weights on each death of S(t)p, where S(t) is the Kaplan-Meier estimate of survival. With

rho = 0 this is the log-rank or Mantel-Haenszel test, and with rho = 1 it is equivalent to the Peto & Peto modification of the Gehan-Wilcoxon test. As result, there is no significant difference (p=0.7) between the survival curves of low risk patients with radiation and those without radiation.

-How many of your patients probably have used gene based biomarkers (Oncotype or mammoprint)? As recent trials show, they may influenced the patient treatment and outcomes.

At the time of data collection between 2001 and 2009 multigene expression assays were not the standard of care. So, for this retrospective analysis we do not know if individual patients received biomarker testing. But we agree that for further studies there will be subgroups of patients in which the multi gene expression assays will provide further helpful information and will also influence the patient\`s decision on treatment strategy.

Minor points:

-Please cite related articles (PMID: 29132568, PMID: 28746732 and PMID: 31451977)

We cited the related articles

-Please indicate in the main text, not in the supplement, that the ethical approval has been reviewed and obtained.

We indicated that ethical approval has been obtained in the main text.

Reviewer \#1: You state" The treatment of elderly breast cancer patients differs from the therapeutic approach in younger ones, as elderly patients are prone to geriatric frailty and comorbidities, such as renal failure, 94 liver disease, and/or cerebrovascular disease (3-5)."

Please add that the treatment also changes because the cancers are less aggressive (Even within ER +, elderly seem more responsive to endocrine therapy as the percent ER positivity is higher.)

Thank you for this important comment. We added in the discussion section that therapeutic strategies in elderly patients often differ from those of younger ones due to less aggressive tumor types.

You over state the benefits of RT:

"After evaluation of different subtypes of breast cancer, it is obvious that even those with less aggressive molecular types profit from radiotherapy. In different meta analyses, hazard ratios of 0.2-0.35 have been described meaning that up to eight of ten relapses can be avoided by RT (6-8). As a result of the improved local tumor control, it has been previously stated that breast cancer related mortality has been significantly decreased during the last decades (6). Therefore, it has been a general recommendation to perform BCT only in combination with postoperative radiotherapy (9). If patients cannot or will not accept postoperative RT, mastectomy is the alternative surgical treatment (10). However, subgroups have been defined that are associated with a low risk for recurrence (pT1, pN0, R0, HER2-) (11, 12). In those cases, radiotherapy still adds benefits but can most likely be dispensed even after BCT."

No randomized trial has shown a survival benefit to RT in early breast cancer.

In the cited meta-analysis by the EBCTCG 17 randomized trials were analyzed and showed that RT to the breast reduced the breast cancer death rate by about a sixth.

Always state "locoregional" recurrence, as RT has no impact on distant recurrence in randomized trials.

Thank you for this comment. We have changed the section to make clear that we talk about locoregional recurrence.

You never defined intermediate vs high risk or separated out those groups. These need to be defined.

In fact, we revised the manuscript and only have 2 groups now: low-risk patients who do not need additional radiation therapy and patients at higher-risk who seem to need radiation therapy.

You combine intermediate and high risk into a single group without showing that they act similarly. You need to describe why you made this combination. When we analyzed our data we found that the major differences occurred between low-risk patients and others. As mentioned above we no longer differentiate between intermediate and high risk patients.

In some places you state high risk benefits and in others that intermediate or high risk benefits, but I do not see these differentiated in your data.

Thank you for this comment. We adjusted the article accordingly. We no longer differentiate between intermediate and high risk patients, instead we use the term higher risk.

Your intermediate group likely contains patients that fit the randomized trials that showed RT has not beneficial. (Such as a 1 cm Grade 3 cancer.). If you are using retrospective data to invalidate the conclusions of a randomized trial, please state why you think this is defensible.

We would really like to correct this issue since we don\`t try to use retrospective data to invalidate the conclusions of the randomized trial CALGB 9343. Hughes et al. included patients \>69 years with T1N0 ER+ breast cancer only. In this trial they did not differentiate between intrinsic subtypes. They found a small decrease in IBTR but no significant benefit in survival.

When you state that limiting your analysis to 9343 criteria, are you including intermediate and high risk patients who meet that criteria? If so, does that negate your statement that intermediate and high risk need RT?

Thank you for this interesting comment. A similar question can be asked for CALGB 9343. A better way to think of risk is as the possibility or probability of recurrence or death. Therefore, patients at higher risk without RT have a higher probability of recurrence or death compared to low risk patients. Nevertheless, there are patients at higher risk without RT, who have no recurrent disease. In the CALGB 9343 trial, as well as this study two types of low risk patients are defined, which both don´t need RT. Therefore, we can combine these two subsets to a new subset of low risk patients. For this combined subgroup we have no significant difference in recurrence free survival (log rank (Mantel-Cox) p=0.958) and tumor associated survival (log rank p= 0.506)

Reviewer \#2: The manuscript here is technically sound and adds additional important information to the literature using a relatively large database of elderly women with breast cancer. The manuscript could be simpler and clearer and my suggestions are below:

1\. The use of the terms BCT with and without RT is confusing. If I'm not mistaken breast conserving therapy without radiotherapy should be referred to as BCS (breast conserving surgery). BCT implies the use of radiotherapy.

Thank you very much for this important issue. We have revised the terms.

2\. I generally disagree with intro lines 102-104. There has been enough data on low risk patients with small tumors having low recurrence rates without radiotherapy that these statements do not apply in 2019.

Thank you very much for this comment. We have clarified the introduction.

3\. I'm not sure why the authors separated the groups out by low and intermediate/high. They define the patients that they place in this intermediate/high group but never define the difference between intermediate and high. This should be defined at some point.

Since reviewer 1 discussed the same issue we would kindly refer to the statement further above.

4\. There are a great deal of words in the paragraph called "basic characteristics" and it is a difficult read. It is essentially explaining Table 1. The paragraph could be started by simply stating that "Basic patient characteristics are listed in Table 1" and then just point out a couple of important distinctions. I do not feel this large paragraph is necessary.

We have revised the section in order to shorten the paragraph.

5\. I find the terms throughout the manuscript of guideline adherent and guideline non-adherent confusing. One could simply state that guidelines state that radiotherapy is indicated and compare the difference between those having it and those not having it. It also makes the Figures showing relapse free and overall survival confusing.

Thank you for this comment. We think that it is quite interesting to see in how many cases RT was not carried out even though the national guidelines would have recommended to do (at least 27,3 %!). Around 30% of those were of intermediate- and high-risk tumors and we showed that those patients profited from RT.

6\. Discussion could be much simpler. Prime 2 and CALGB trials are referenced early on and then a paragraph is allotted to each one later in the discussion. I would just acknowledge each randomized control trial once and shorten discussion.

We adjusted the discussion according your recommendation.

7\. Overall useful information particularly regarding the higher risk group but could be more simply and clearly presented.

We tried to reword the manuscript in order to achieve a clearer presentation.

###### 

Submitted filename: Responsetoreviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0229518.r003

Decision Letter 1

Zhang

Lanjing

Academic Editor

© 2020 Lanjing Zhang

2020

Lanjing Zhang

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Feb 2020

Effect of adjuvant radiotherapy in elderly patients with breast cancer

PONE-D-19-28656R1

Dear Dr. Stueber,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Lanjing Zhang, MD, MS

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Revisions seem correct to me at this time in reading these comments. Thank you for your revisions This seems fine

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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Dear Dr. Stueber:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Lanjing Zhang

Academic Editor

PLOS ONE
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